Page last updated: 2024-11-07

tetrahydrocortisol and Overweight

tetrahydrocortisol has been researched along with Overweight in 1 studies

Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.

Research Excerpts

ExcerptRelevanceReference
"To study the oral 11 beta-hydroxysteroid dehydrogenase-1 (11β-HSD1) inhibitor BI 187004 (NCT02150824), as monotherapy and in combination with metformin, versus placebo in patients with type 2 diabetes mellitus (T2DM) affected by overweight or obesity."5.69Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity. ( Bianzano, S; Heise, T; Nordaby, M; Peil, B; Plum-Mörschel, L, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bianzano, S2
Nordaby, M2
Plum-Mörschel, L2
Peil, B2
Heise, T2

Trials

1 trial available for tetrahydrocortisol and Overweight

ArticleYear
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans

2023